Adapt Pharma said today that it filed a European Marketing Application for its naloxone hydrochloride nasal spray for the treatment of opioid overdose.
The Dublin-based company’s product is a ready-to-use, needle-free device that delivers a single dose of naloxone in an 0.1 mL nasal spray and does not require assembly prior to use, according to Adapt Pharma.
Get the full story at our sister site, Drug Delivery Business News.
The post Adapt Pharma seeks regulatory nod for naloxone nasal spray in Europe appeared first on MassDevice.
from MassDevice http://ift.tt/2mildF3
Cap comentari:
Publica un comentari a l'entrada